Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765557 | 0.94 | L3MBTL1 (0.40) | L3MBTL1PTPN7DUSP3EPHX2P2RX7 | |
| SCHEMBL765833 | 0.93 | L3MBTL1 (0.40) | L3MBTL1PTPN7DUSP3EPHX2KMT2A | |
| SCHEMBL764478 | 0.93 | PPARA (0.41) | L3MBTL1PTPN7DUSP3EPHX2KMT2A | |
| SCHEMBL764439 | 0.93 | L3MBTL1 (0.40) | L3MBTL1PTPN7DUSP3EPHX2KMT2A | |
| SCHEMBL765102 | 0.92 | L3MBTL1 (0.39) | L3MBTL1PTPN7DUSP3EPHX2KMT2A | |
| SCHEMBL764502 | 0.90 | L3MBTL1 (0.38) | L3MBTL1PTPN7DUSP3EPHX2KMT2A | |
| SCHEMBL764479 | 0.90 | CNR1 (0.41) | L3MBTL1PTPN7DUSP3EPHX2 | |
| SCHEMBL764477 | 0.90 | L3MBTL1 (0.41) | L3MBTL1PTPN7DUSP3EPHX2P2RX7 | |
| SCHEMBL10121227 | 0.90 | EPHX2 (0.44) | L3MBTL1PTPN7DUSP3EPHX2P2RX7 | |
| SCHEMBL10121546 | 0.89 | L3MBTL1 (0.39) | L3MBTL1PTPN7DUSP3EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | L3MBTL1 2516/4885PTPN7 4300/4885DUSP3 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.